← Leaderboards
David A Barbie
Dana-Farber Cancer Inst
$12,794,638
Attributed
$17,380,846
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2010–25$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,455,256 · 15
By mechanism
P50$13,762,260 · 10
U01$7,752,681 · 2
R01$4,002,350 · 1
K08$891,000 · 1
P30$46,965 · 1
Top collaborators
- Roger D. Kamm5 shared
- Lecia V. Sequist4 shared
- Robert I. Haddad1 shared
- Ravindra Uppaluri1 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Ursula Anne Matulonis$3,602,637
- Patrick Alexander Ott$3,127,186
- Piotr Sicinski$42,703,610
- Alan David D'andrea$28,094,196
- Brian Matthew Wolpin$8,665,523
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungTumorClinical TrialsLaboratoriesMutationMalignant NeoplasmsResponseTargeted TreatmentCellsCombined Modality TherapySignal TransductionMutantResistanceCancer CenterPathway InteractionsSpecimenPre-ClinicalIn VivoTranslational ResearchCancer CellOncogenesImmuneBaseCell Survival
Grant awards (41)
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer$2,250,699
P50 · FY2025 · CA · contact PI
Project 2$423,518
P50 · FY2025 · CA · contact PI
Pathology & Genomics$366,835
P50 · FY2025 · CA · contact PI
Admin Core$254,300
P50 · FY2025 · CA · contact PI
Program 34: Lung Cancer$46,965
P30 · FY2025 · CA · contact PI
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer$2,250,220
P50 · FY2024 · CA · contact PI
Targeting the cytokine circuitry of KRAS-driven lung cancer$394,956
R01 · FY2024 · CA · contact PI
Project 2$388,732
P50 · FY2024 · CA · contact PI
Admin Core$321,185
P50 · FY2024 · CA · contact PI
Pathology & Genomics$314,961
P50 · FY2024 · CA · contact PI
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer$2,189,154
P50 · FY2023 · CA · contact PI
Targeting the cytokine circuitry of KRAS-driven lung cancer$407,428
R01 · FY2023 · CA · contact PI
Project 2$379,776
P50 · FY2023 · CA · contact PI
Admin Core$312,231
P50 · FY2023 · CA · contact PI
Pathology & Genomics$306,005
P50 · FY2023 · CA · contact PI
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer$2,384,337
P50 · FY2022 · CA · contact PI
Project 2$421,290
P50 · FY2022 · CA · contact PI
Targeting the cytokine circuitry of KRAS-driven lung cancer$407,428
R01 · FY2022 · CA · contact PI
Pathology & Genomics$345,895
P50 · FY2022 · CA · contact PI
Admin Core$332,759
P50 · FY2022 · CA · contact PI
Biostatistics Core$255,422
P50 · FY2022 · CA · contact PI
Career Enhancement Program$135,775
P50 · FY2022 · CA · contact PI
Developmental Research Program$129,166
P50 · FY2022 · CA · contact PI
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade$826,420
U01 · FY2021 · CA
Targeting the cytokine circuitry of KRAS-driven lung cancer$415,743
R01 · FY2021 · CA · contact PI
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade$676,329
U01 · FY2020 · CA
Targeting the cytokine circuitry of KRAS-driven lung cancer$415,743
R01 · FY2020 · CA · contact PI
Defining mechanisms of immunotherapy resistance in head and neck squamous cell carcinomas$4,259,203
U01 · FY2019 · DE
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade$678,954
U01 · FY2019 · CA
Targeting the cytokine circuitry of KRAS-driven lung cancer$382,740
R01 · FY2019 · CA · contact PI
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade$737,605
U01 · FY2018 · CA
Targeting the cytokine circuitry of KRAS-driven lung cancer$394,578
R01 · FY2018 · CA · contact PI
Development of Physiologic Tissue Models to Assess Tumor Explant Response to Immune Checkpoint Blockade$574,170
U01 · FY2017 · CA
Targeting the cytokine circuitry of KRAS-driven lung cancer$394,578
R01 · FY2017 · CA · contact PI
Targeting the cytokine circuitry of KRAS-driven lung cancer$394,578
R01 · FY2016 · CA · contact PI
Targeting the cytokine circuitry of KRAS-driven lung cancer$394,578
R01 · FY2015 · CA · contact PI
Synthetic-Lethal-Based Targeted Therapy for Oncogenic KRAS-Driven Cancer$178,200
K08 · FY2014 · CA · contact PI
Synthetic-Lethal-Based Targeted Therapy for Oncogenic KRAS-Driven Cancer$178,200
K08 · FY2013 · CA · contact PI
Synthetic-Lethal-Based Targeted Therapy for Oncogenic KRAS-Driven Cancer$178,200
K08 · FY2012 · CA · contact PI
Synthetic-Lethal-Based Targeted Therapy for Oncogenic KRAS-Driven Cancer$178,200
K08 · FY2011 · CA · contact PI
Synthetic-Lethal-Based Targeted Therapy for Oncogenic KRAS-Driven Cancer$178,200
K08 · FY2010 · CA · contact PI